217 related articles for article (PubMed ID: 22104762)
1. Update on the use of cinacalcet in the management of primary hyperparathyroidism.
Marcocci C; Cetani F
J Endocrinol Invest; 2012 Jan; 35(1):90-5. PubMed ID: 22104762
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet in the management of primary hyperparathyroidism.
Cetani F; Marcocci C
Expert Rev Endocrinol Metab; 2012 Jan; 7(1):45-53. PubMed ID: 30736110
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
Duntas LH; Stathatos N
Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
[TBL] [Abstract][Full Text] [Related]
6. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet for the treatment of primary hyperparathyroidism.
Dillon ML; Frazee LA
Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
[TBL] [Abstract][Full Text] [Related]
8. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci B; Comlekci A; Tankurt E
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.
Marcocci C; Chanson P; Shoback D; Bilezikian J; Fernandez-Cruz L; Orgiazzi J; Henzen C; Cheng S; Sterling LR; Lu J; Peacock M
J Clin Endocrinol Metab; 2009 Aug; 94(8):2766-72. PubMed ID: 19470620
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.
Chandran M; Bilezikian JP; Lau J; Rajeev R; Yang SP; Samuel M; Parameswaran R
Rev Endocr Metab Disord; 2022 Jun; 23(3):485-501. PubMed ID: 35041148
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.
Manaka K; Sato J; Kinoshita Y; Ito N; Fujita M; Iiri T; Nangaku M; Makita N
Endocr J; 2019 Aug; 66(8):683-689. PubMed ID: 31092749
[TBL] [Abstract][Full Text] [Related]
13. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
Muñoz Torres M; García Martín A
Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
[TBL] [Abstract][Full Text] [Related]
18. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
[TBL] [Abstract][Full Text] [Related]
19. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group.
Saponaro F; Faggiano A; Grimaldi F; Borretta G; Brandi ML; Minisola S; Frasoldati A; Papini E; Scillitani A; Banti C; Del Prete M; Vescini F; Gianotti L; Cavalli L; Romagnoli E; Colao A; Cetani F; Marcocci C
Clin Endocrinol (Oxf); 2013 Jul; 79(1):20-6. PubMed ID: 23228121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
